Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
In highly experienced HIV-1-infected patients, a ritonavir-boosted darunavir-containing regimen was associated with dramatic immunological and virological efficacy. Patients harbouring viruses with amprenavir-specific resistance profiles, such as I50V or V32I + I47V, failed on a darunavir/ritonavir-containing regimen. These key amprenavir mutations were also selected at the time of failure, suggesting their impact on darunavir efficacy.
Delaugerre
Constance
C
Department of Virology, Ambroise Pare Hospital, APHP, Boulogne, France.
Mathez
Dominique
D
Peytavin
Gilles
G
Berthé
Huguette
H
Long
Kivan
K
Galperine
Tatiana
T
de Truchis
Pierre
P
D018791:CD4 Lymphocyte Count; D002219:Carbamates / Q000627:therapeutic use*; D000069454:Darunavir; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D019438:Ritonavir / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*; D017211:Treatment Failure; D019562:Viral Load
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D019438:Ritonavir; D000069454:Darunavir